|
|
|
|
|
|
|
|
open access:
Primary Peritoneal Carcinoma in a BRCA1/2-negative, PALB2-positive patient
Highlights
- • First reported case of PPC after BSO in a BRCA1/2-negative, PALB2-positive patient
- • The PALB2 mutation and genetic counseling is discussed
- • Multi-gene panel testing can benefit prognostic factors and targeted therapy
1. Introduction
Primary
Peritoneal Carcinoma (PPC) is a cancer of the abdominal peritoneal
lining without involvement of the ovaries or identifiable primary tumor.
Its estimated annual incidence in the United States is 0.46 per 100,000
women(Goodman et al., 2009). The actual incidence of low-grade serous PPC is much lower (< 1/150,000) (Rothacker et al., 1995).
Most cases are serous subtype with cellular origin identical to that of
epithelial ovarian carcinoma. PPC often mimics ovarian and fallopian
tube cancers. It accounts for roughly 10% of ovarian carcinomas that
have been presumably misdiagnosed (Rothacker et al., 1995).
Women
undergoing prophylactic bilateral salpingo-oophorectomy (BSO) can still
develop PPC years later, suggesting that certain epithelial peritoneal
cancers do not originate from the ovarian surface. Instead, ovarian
epithelial tumors and PPC are hypothesized to share a common embryologic
origin with similar germline and somatic mutations. In current
literature, nearly all PPC cases have been reported in women with a
known BRCA1/2 germline mutation. However, there have been minimal studies on genetic testing outside of BRCA1/2 mutations in patients with PPC. Here, we report a case of a BRCA1/2-negative
patient who had undergone prophylactic BSO and presented years later
with PPC (19 years) and was subsequently found to carry a mutation in PALB2.....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.